AAAnna Abrahamsson

Anna Abrahamsson

*This is an algorithmically generated author record based on publicly available information.

Anna Abrahamsson has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Adam Platt

    Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK

    1 shared publication
  • Britta Bonn

    Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory, Inflammation and Autoimmune (RIA), BioPharmaceuticals R&D, AstraZeneca, 431 83 Gothenburg, Sweden

    1 shared publication
  • Erica Bäckström

    Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory, Inflammation and Autoimmune (RIA), BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden

    1 shared publication
  • Glen Hughes

    Precision Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom

    1 shared publication
  • Jean-François Gautier

    INEM Institut Necker-Enfants Malades, INSERM U1151, CNRS UMR 8253, Université Paris Cité, Paris, France; Centre Universitaire du Diabète et de ses Complications, AP-HP, Hôpital Lariboisière, INSERM UMR-S1151, CNRS UMR-S8253, Immediab Lab, Institut Necker-Enfants Malades, Université Paris Cité, Paris, France

    1 shared publication
  • Jean-Marie Launay

    Biochemistry and Molecular Laboratory, Lariboisière Hospital, 75019 Paris, France

    1 shared publication

Latest Publications

  • Open Access

    Pulmonary Metabolism of Substrates for Key Drug-Metabolizing Enzymes by Human Alveolar Type II Cells, Human and Rat Lung Microsomes, and the Isolated Perfused Rat Lung Model

    by Katarina Rubin, Pär Ewing, Erica Bäckström, Anna Abrahamsson, Britta Bonn, Satoshi Kamata, Ken Grime

    Significant pulmonary metabolism of inhaled drugs could have drug safety implications or influence pharmacological effectiveness. To study this in vitro, lung microsomes or S9 are often employed. Here, we have determined if rat and human lung microsomes are fit for purpose or whether it is better to use specific cells where drug-metabolizing enzymes are concentrated, such as alveolar type II (ATII) cells. Activities for major hepatic and pulmonary human drug-metabolizing enzymes are assessed and the data contextualized towards an in vivo setting using an ex vivo isolated perfused rat lung model. Very low rates of metabolism are observed in incubations with human ATII cells when compared to isolated hepatocytes and fewer of the substrates are found to be metabolized when compared to human lung microsomal incubations. Reactions selective for flavin-containing monooxygenases (FMOs), CYP1B1, CYP2C9, CYP2J2, and CYP3A4 all show significant rates in human lung microsomal incubations, but all activities are higher when rat lung microsomes are used. The work also demonstrates that a lung microsomal intrinsic clearance value towards the lower limit of detection for this parameter (3 µL/min/mg protein) results in a very low level of pulmonary metabolic clearance during the absorption period, for a drug dosed into the lung in vivo.


  • Open Access

    Accuracy of the HumaSensplus point-of-care uric acid meter using capillary blood obtained by fingertip puncture

    by Stéphanie Fabre, Pierre Clerson, Jean-Marie Launay, Jean-François Gautier, Tiphaine Vidal-Trecan, Jean-Pierre Riveline, Adam Platt, Anna Abrahamsson, Jeffrey N. Miner, Glen Hughes, et al.

    The uric acid (UA) level in patients with gout is a key factor in disease management and is typically measured in the laboratory using plasma samples obtained after venous puncture. This study aimed to assess the reliability of immediate UA measurement with capillary blood samples obtained by fingertip puncture with the HumaSensplus point-of-care meter. UA levels were measured using both the HumaSensplus meter in the clinic and the routine plasma UA method in the biochemistry laboratory of 238 consenting diabetic patients. HumaSensplus capillary and routine plasma UA measurements were compared by linear regression, Bland-Altman plots, intraclass correlation coefficient (ICC), and Lin’s concordance coefficient. Values outside the dynamic range of the meter, low (LO) or high (HI), were analyzed separately. The best capillary UA thresholds for detecting hyperuricemia were determined by receiver operating characteristic (ROC) curves. The impact of potential confounding factors (demographic and biological parameters/treatments) was assessed. Capillary and routine plasma UA levels were compared to reference plasma UA measurements by liquid chromatography-mass spectrometry (LC-MS) for a subgroup of 67 patients. In total, 205 patients had capillary and routine plasma UA measurements available. ICC was 0.90 (95% confidence interval (CI) 0.87–0.92), Lin’s coefficient was 0.91 (0.88–0.93), and the Bland-Altman plot showed good agreement over all tested values. Overall, 17 patients showed values outside the dynamic range. LO values were concordant with plasma values, but HI values were considered uninterpretable. Capillary UA thresholds of 299 and 340 μmol/l gave the best results for detecting hyperuricemia (corresponding to routine plasma UA thresholds of 300 and 360 μmol/l, respectively). No significant confounding factor was found among those tested, except for hematocrit; however, this had a negligible influence on the assay reliability. When capillary and routine plasma results were discordant, comparison with LC-MS measurements showed that plasma measurements had better concordance: capillary UA, ICC 0.84 (95% CI 0.75–0.90), Lin’s coefficient 0.84 (0.77–0.91); plasma UA, ICC 0.96 (0.94–0.98), Lin’s coefficient 0.96 (0.94–0.98). UA measurements with the HumaSensplus meter were reasonably comparable with those of the laboratory assay. The meter is easy to use and may be useful in the clinic and in epidemiologic studies.